Global Oral Vaccine Market Size By Type (Product Type I, Product Type II), By Application (Application I, Application II), By Region, And Segment Forecasts, 2023 to 2032

The Global Oral Vaccine Market was valued at USD 7.6 billion in 2023 and is projected to reach USD 14.1 billion by 2031, growing at a CAGR of 7.8% during the forecast period from 2023 to 2031. The market's expansion is driven by the growing prevalence of infectious diseases, increasing immunization programs by global health authorities, and rising demand for needle-free, patient-friendly vaccination methods. Oral vaccines are transforming the vaccine landscape by improving accessibility, reducing the need for healthcare infrastructure, and enhancing compliance, especially in low-resource settings.

Drivers

1. Rising Incidence of Infectious Diseases

The resurgence of diseases such as cholera, rotavirus, and polio—especially in developing regions—has heightened the demand for oral vaccines due to their effectiveness in mass immunization campaigns.

2. Government and WHO Immunization Initiatives

Ongoing support from health organizations such as the WHO, UNICEF, and GAVI for oral vaccine deployment—particularly in pediatric and underserved populations—continues to bolster market growth.

3. Growing Preference for Needle-Free Vaccination

Needle-phobia among children and adults, along with the risk of cross-contamination with injectable vaccines, has made oral vaccines a preferred alternative, especially in school-based and community settings.

Restraints

1. Cold Chain Dependency and Storage Issues

Many oral vaccines require strict cold storage and transportation conditions, posing a logistical challenge in remote and underdeveloped areas.

2. Variable Immune Response

Compared to injectable vaccines, oral formulations can sometimes show reduced immunogenicity due to degradation in the gastrointestinal tract, limiting their application for certain diseases.

Opportunity

1. Technological Advancements in Oral Vaccine Delivery

Breakthroughs in drug delivery mechanisms, including nanoparticle and enteric-coated systems, are enhancing the bioavailability and stability of oral vaccines, creating new pathways for market expansion.

2. Expansion into Emerging Markets

Increased healthcare funding, improving infrastructure, and government-led vaccination initiatives across Asia-Pacific, Latin America, and Africa provide a fertile ground for the oral vaccine market.

3. Pandemic Preparedness and Innovation

The COVID-19 pandemic highlighted the need for flexible vaccination platforms. Ongoing R&D efforts aim to develop oral vaccines for COVID-19 variants and other pandemic-prone viruses.

Market by System Type Insights

By system type, the Live Attenuated Vaccines segment held the largest share in 2023. These vaccines offer strong immunity with fewer doses and are widely used for diseases like polio and rotavirus. However, Inactivated Vaccines are projected to grow rapidly due to their safety profile, especially for immunocompromised individuals.

Market by End-Use Insights

In 2023, the Pediatric Segment was the largest end-use segment, contributing over 60% of the global revenue. The segment's dominance is driven by routine immunization schedules and school-based vaccination programs. Meanwhile, the Adult and Geriatric Segment is expected to experience notable growth due to increasing awareness and adult vaccination campaigns for diseases like cholera and typhoid.

Market by Regional Insights

Asia-Pacific emerged as the largest regional market in 2023, accounting for over 35% of the global revenue. This growth is attributed to high birth rates, strong governmental immunization policies, and significant health funding. North America follows closely, driven by technological innovation, strong regulatory frameworks, and the presence of major players. Africa and Latin America are forecasted to witness the highest growth rates due to rising healthcare outreach and global health funding.

Competitive Scenario

Key players in the Global Oral Vaccine Market include:

GlaxoSmithKline plc

Sanofi S.A.

Merck & Co., Inc.

Bharat Biotech

Valneva SE

Vaxart, Inc.

Emergent BioSolutions Inc.

These companies focus on strategic R&D investments, global partnerships, and licensing agreements to innovate and expand their oral vaccine portfolios. For instance:

In 2024, Vaxart announced promising Phase II results for its oral norovirus vaccine candidate.

Sanofi collaborated with global NGOs in 2023 to roll out oral cholera vaccines in sub-Saharan Africa.

Bharat Biotech expanded its manufacturing capacity for oral rotavirus vaccines in 2023 to meet global demand.

Scope of Work – Global Oral Vaccine Market

Report Metric Details

Market Size (2023) USD 7.6 Billion

Projected Market Size (2031) USD 14.1 Billion

CAGR (2023–2031) 7.8%

Market Segments By System Type, By End-Use, Region

Growth Drivers Rising infectious disease burden, needle-free delivery demand, global immunization campaigns

Opportunities Tech innovations, emerging markets, pandemic preparedness

Key Market Developments

2024: Vaxart began Phase III trials for its COVID-19 oral vaccine platform targeting both domestic and international markets.

2023: Bharat Biotech secured WHO prequalification for its new generation oral rotavirus vacci